Table 4.
Changes in aqueous humor contents of cytokines in the myopic CNV group after ranibizumab injections
| At baseline | At 1 month | p valuef | At 2 months | p valueg | p valueh | |
|---|---|---|---|---|---|---|
| VEGF-A (pg/mL) | 135.09 ± 70.29 | 5.41 ± 0.58 | 0.000 | 8.33 ± 4.70 | 0.000 | 0.389 |
| VEGF-C (pg/mL) | 2.99 ± 0.39 | 2.84 ± 0.41 | 0.723 | 2.32 ± 0.16 | 0.739 | 0.525 |
| VEGF-D (pg/mL) | 2.99 ± 0.39 | 2.84 ± 0.41 | 0.264 | 2.32 ± 0.16 | 0.000 | 0.002 |
| EGF (pg/mL) | 0.64 ± 0.08 | 0.71 ± 0.17 | 0.150 | 0.78 ± 0.09 | 0.010 | 0.171 |
| Angiopoietin-2 (pg/mL) | 33.04 ± 12.94 | 31.41 ± 8.75 | 0.689 | 30.76 ± 10.22 | 0.624 | 0.891 |
| Endoglin (pg/mL) | 15.41 ± 1.35 | 14.76 ± 1.83 | 0.257 | 11.69 ± 1.19 | 0.000 | 0.000 |
| FGF-1 (pg/mL) | 4.75 ± 1.10 | 4.83 ± 1.35 | 0.848 | 4.05 ± 0.82 | 0.156 | 0.119 |
| FGF-2 (pg/mL) | 46.34 ± 52.41 | 27.77 ± 18.68 | 0.167 | 17.79 ± 10.08 | 0.064 | 0.513 |
| IL-8 (pg/mL) | 6.47 ± 3.81 | 4.86 ± 1.82 | 0.139 | 5.33 ± 2.20 | 0.351 | 0.702 |
| HGF (pg/mL) | 1406.75 ± 820.44 | 1330.27 ± 83.62 | 0.813 | 1218.26 ± 981.87 | 0.608 | 0.764 |
| HB-EGF (pg/mL) | 1.26 ± 0.33 | 1.27 ± 0.25 | 0.978 | 1.33 ± 0.29 | 0.607 | 0.629 |
| PLGF (pg/mL) | 2.74 ± 1.08 | 1.94 ± 1.07 | 0.546 | 1.76 ± 0.89 | 0.531 | 0.674 |
VEGF vascular endothelial growth factor, EGF epidermal growth factor, FGF fibroblast growth factor, IL-8 interleukin-8, HGF hepatocyte growth factor, HB-EGF heparin-binding epidermal growth factor, PLGF placental growth factor
fOne-way analysis of variance (ANOVA) between baseline and 1 month for changes in aqueous humor contents of cytokines
gANOVA between baseline and 2 months for changes in aqueous humor cytokine contents
hANOVA between 1 and 2 months for changes in aqueous humor contents of cytokines